HS
ORIC icon

HighVista Strategies’s Oric Pharmaceuticals ORIC Stock Holding History

HighVista Strategies’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,333
Closed -$547K – 133
2021
Q1 		$547K Buy
+22,333
New +$706K 0.41% 64

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

HighVista Strategies's ORIC Position: Q2 2021 in Review

HighVista Strategies sold out of Oric Pharmaceuticals (ORIC) in Q2 2021, closing a stake of 22,333 shares — an estimated $547K sold.

HighVista Strategies first reported a position in ORIC in Q1 2021 and held it in 1 quarter. The position peaked at $547K in Q1 2021. 78 funds tracked by Wall St. Rank hold ORIC as of Q2 2021.

  • HighVista Strategies reported no remaining Oric Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 22,333 Oric Pharmaceuticals shares in Q2 2021, an estimated $547K.
  • HighVista Strategies first reported a position in Oric Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • HighVista Strategies's Oric Pharmaceuticals position peaked at $547K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.